JPRN-jRCT2031220742招募中1 期
A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations
Calleja Elizabeth0 个研究点目标入组 200 人开始时间: 2023年4月24日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Locally advanced, non-resectable or metastatic NSCLC
- •- Have adequate organ function
- •- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- •- Has tumor tissue available to allow for analysis of EGFRmt status
- •Dose Escalation: Has any EGFRmt status
- •Dose Escalation back-fill part, Dose Expansion and Phase II: Has any sensitizing EGFRmt and a confirmed C797S EGFRmt
- •- Has measurable disease per RECIST v1.1
排除标准
- •- Participating in medical research not compatible with this study
- •- Symptomatic and unstable CNS metastases
- •- Have not recovered from prior cancer treatment
- •- Have a significant cardiac condition
- •- Are a pregnant or breastfeeding female
- •- A serious illness or medical condition
- •- Unable to swallow or digest pills
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR MutationsPatients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2022-502595-23-00Taiho Oncology Inc.102
终止
1 期
A Study of TAS3351 in NSCLC Patients With EGFRmtNon-Small Cell Lung CancerNCT05765734Taiho Oncology, Inc.18
暂停
1 期
TAS0313 Phase I/II studySolid tumor (urothelial carcinoma, and so on)JPRN-jRCT2080223768Taiho Pharmaceutical Co., Ltd.130
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-ATTaiho Oncology, Inc.100
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-FRTaiho Oncology, Inc.100